Skip to main content
. Author manuscript; available in PMC: 2013 Jul 31.
Published in final edited form as: J Hepatol. 2010 Dec 15;55(2):315–321. doi: 10.1016/j.jhep.2010.11.020

Table 4.

Summary of HRS reversal and survival by concomitant beta-blocker use.

Terlipressin (n = 56)
Placebo (n = 56)
n % 95% CI n % 95% CI
Received concomitant beta-blockers
 HRS reversal 8/16 50 25–75 2/23 9 1–28
 180-day survival estimate - 56 - - 35 -

Did not receive concomitant beta-blockers
 HRS reversal 11/40 28 15–44 5/33 15 5–32
 180-day survival estimate - 38 - - 39 -

95% CI: 95% confidence intervals.